New study using psilocybin to treat depression

magic_mushrooms

Psilocybin, the psychoactive compound from magic mushrooms, is being used to treat depression and anxiety in terminally ill patients in a new trial at Melbourne’s St Vincent’s Hospital.

The trial, headed by St Vincent’s clinical psychologist Dr Margaret Ross, will begin in April with 30 patients recruited from the hospital’s palliative care who have not responded to anti-depressant or anti-anxiety therapies.

The patients will be given a single dose of 25mg of synthetic psilocybin in conjunction with psychotherapy sessions.

Ross told BuzzFeed News that this a mid-range dosage that will provide patients with a psychedelic experience that will last in the range of four hours but they will be supervised for up to eight hours after the psilocybin has worn off.

“We don’t want it to be underwhelming, we don’t want it to be overwhelming,” she said.

Read more: https://www.buzzfeed.com/elfyscott/australias-first-psychedelics-trial-is-about-to-use-magic

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.

PRISM

We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.

Newsletter

Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search